Program
ontunisertib
Also written as “Ontunisertib”, “AGMB-129” and “[14C]ontunisertib”.
Its studies are mostly in Crohn Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agomab Therapeutics NV | 62 open or running | phase 2since Apr 25, 2023 | Apr 25, 2023 | Dec 31, 2028phase 2 · NCT07683325 |
| Origo Biopharma | 10 open or running | phase 1since Jun 18, 2021 | Jun 18, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 18, 2021First study: phase 1 study in Healthy VolunteersNew to Origo BiopharmaOrigo Biopharma · NCT04933565 · 81 enrolled · Spain
- Apr 25, 2023Agomab Therapeutics NV's first study: phase 2 study in Fibrostenotic Crohn's DiseaseNew to Agomab Therapeutics NVAgomab Therapeutics NV · NCT05843578 · 103 enrolled · United States, Austria, Canada and more
- Jun 30, 2023Phase 1 study in Healthy VolunteersAgomab Therapeutics NV · NCT05937386 · 14 enrolled · Belgium
- Apr 30, 2024Phase 1 study in Healthy VolunteersAgomab Therapeutics NV · NCT06397508 · 25 enrolled · Belgium
- Jul 28, 2025Phase 1 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07118878 · 30 enrolled · Belgium
- Jun 12, 2026Phase 1 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07672574 · 8 planned · United Kingdom
- Jun 24, 2026Phase 2 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07683325 · 320 planned · United States, Serbia, United Kingdom
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07683325
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07683325Fibrostenotic Crohn's Disease · United States, Serbia, United Kingdom | 2 | Recruiting | Agomab Therapeutics NV | Dec 31, 2028 | 320 |
| NCT07672574Fibrostenotic Crohn's Disease · United Kingdom | 1 | Recruiting | Agomab Therapeutics NV | Sep 26, 2026 | 8 |
| NCT07118878Fibrostenotic Crohn's Disease · Belgium | 1 | Completed | Agomab Therapeutics NV | Sep 15, 2025 | 30 |
| NCT06397508Healthy Volunteers · Belgium | 1 | Completed | Agomab Therapeutics NV | May 8, 2024 | 25 |
| NCT05937386Healthy Volunteers · Belgium | 1 | Completed | Agomab Therapeutics NV | Sep 6, 2023 | 14 |
| NCT05843578Fibrostenotic Crohn's Disease · United States, Austria, Canada and more | 2 | Completed | Agomab Therapeutics NV | Jun 20, 2026 | 103 |
| NCT04933565Healthy Volunteers · Spain | 1 | Completed | Origo Biopharma | Dec 12, 2022 | 81 |
How it is read
Names in the registry
- “Ontunisertib”, 4 entries
- “AGMB-129”, 4 entries
- “[14C]ontunisertib”, 2 entries
- “ORG-129”, 1 entry
Conditions, from the studies’ own filings
- Crohn Disease, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.